Legend Biotech (LEGN) disclosed late Monday new results from a phase 3 study showing a single infusion of Carvykti provided "significantly higher" rates of minimal residual disease-negativity in patients with relapsed or lenalidomide-refractory multiple myeloma.
The medication is for patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
The company said that 89% of evaluable patients achieved minimal residual disease negativity with Carvykti after a three-year follow-up in the study, with the "majority in less than 2 months." The results "add" to the overall survival benefit recently reported.
"The latest MRD data showcases the advances of Carvykti and further demonstrates why it is a leading treatment for patients with multiple myeloma," said Ying Huang, chief executive officer of Legend Biotech.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。